---
id: neutropenic-fever_115
category: clinical_syndromes
tags: [neutropenic-fever, febrile-neutropenia, chemotherapy, high-risk, empiric-therapy]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Neutropenic Fever

**Q:** What is the definition, risk stratification, empiric treatment, and management approach for neutropenic fever?

**A:**

## DEFINITION

**Neutropenic Fever:**
- **Neutropenia:** ANC (Absolute Neutrophil Count) **<500 cells/μL** OR <1000 cells/μL with predicted decline to <500
- **Fever:** Single oral temperature **≥38.3°C (101°F)** OR ≥38.0°C (100.4°F) sustained over 1 hour

**Key Point:** **Medical emergency** - requires immediate evaluation and empiric antibiotics

---

## RISK STRATIFICATION

### **High-Risk vs Low-Risk**

| **Parameter** | **High-Risk** | **Low-Risk** |
|---------------|---------------|--------------|
| **ANC** | **<100 cells/μL** | 100-500 cells/μL |
| **Duration** | **Prolonged (>7 days)** | Brief (<7 days) |
| **Clinical status** | **Hemodynamically unstable, organ dysfunction** | Stable, outpatient-appropriate |
| **Comorbidities** | **Pneumonia, hypotension, hepatic/renal insufficiency** | None |
| **MASCC score** | **<21** | **≥21** (low-risk) |

**Key Point:** **High-risk = ANC <100, prolonged >7 days, or clinical instability**

---

## MASCC RISK INDEX (Multinational Association for Supportive Care in Cancer)

**Low-Risk (MASCC ≥21):** Candidates for outpatient management OR early discharge

| **Characteristic** | **Points** |
|--------------------|-----------|
| No or mild symptoms | 5 |
| No hypotension | 5 |
| No COPD | 4 |
| Solid tumor or no previous fungal infection | 4 |
| No dehydration | 3 |
| Outpatient at fever onset | 3 |
| Age <60 years | 2 |

**Score:**
- **≥21 = Low-risk** (consider outpatient management with oral antibiotics)
- **<21 = High-risk** (inpatient IV antibiotics required)

**Key Point:** **MASCC ≥21 + clinically stable = outpatient oral antibiotics possible**

---

## EMPIRIC ANTIBIOTIC THERAPY

### **High-Risk Patients (Inpatient IV Therapy)**

**Monotherapy (Preferred for Most Patients):**

| **Agent** | **Dosing** | **Notes** |
|-----------|------------|-----------|
| **Cefepime** | **2g IV q8h** | **1st-line** (broad Gram-neg + Gram-pos coverage) |
| **Piperacillin-tazobactam** | **4.5g IV q6h** | Alternative (broader anaerobic coverage) |
| **Meropenem** | **1g IV q8h** | If resistant organisms or severe sepsis |

**Key Point:** **Cefepime OR piperacillin-tazobactam = 1st-line monotherapy**

---

### **When to Add Vancomycin (Gram-Positive Coverage)**

**Add vancomycin if:**
- **Hemodynamic instability** (septic shock)
- **Pneumonia** (cavitary lesions)
- **Skin/soft tissue infection** (cellulitis, catheter site)
- **Suspected catheter-related bloodstream infection**
- **Blood cultures positive for Gram-positive cocci** (before speciation)
- **Known MRSA colonization**
- **Severe mucositis** (viridans streptococci risk)

**Dosing:** **Vancomycin 15-20 mg/kg IV q8-12h** (target trough 15-20 μg/mL)

**Key Point:** **Do NOT add vancomycin empirically in hemodynamically stable patients**

---

### **When to Add Antifungal Coverage**

**Indications:**
- **Persistent fever ≥4-7 days** despite broad-spectrum antibiotics
- **Prolonged neutropenia (>7 days)**
- **Clinical/radiologic findings suggestive of invasive fungal infection** (IFI)

**Empiric Antifungal Options:**

| **Agent** | **Dosing** | **Coverage** |
|-----------|------------|--------------|
| **Micafungin** | **100 mg IV daily** | **Candida** (yeast) |
| **Caspofungin** | **70 mg IV x 1 → 50 mg IV daily** | Candida, Aspergillus |
| **Voriconazole** | **6 mg/kg IV q12h x 2 → 4 mg/kg IV q12h** | **Candida + Aspergillus** (mold) |
| **Liposomal amphotericin B** | **3 mg/kg IV daily** | Broadest (yeast + mold) |

**Key Point:** **Add empiric antifungal if fever >4-7 days** despite antibiotics

---

### **Low-Risk Patients (Outpatient Oral Therapy)**

**Criteria for Outpatient Management:**
- **MASCC score ≥21**
- **Hemodynamically stable**
- **No organ dysfunction**
- **Expected brief neutropenia (<7 days)**
- **Able to take oral medications**
- **Reliable follow-up**

**Oral Regimen:**

| **Regimen** | **Dosing** |
|-------------|------------|
| **Ciprofloxacin + amoxicillin-clavulanate** | **Cipro 750 mg PO BID + Augmentin 875 mg PO BID** |
| **Levofloxacin + amoxicillin-clavulanate** | **Levo 750 mg PO daily + Augmentin 875 mg PO BID** |

**Key Point:** **Fluoroquinolone + beta-lactam** for outpatient low-risk neutropenic fever

---

## DIAGNOSTIC WORKUP

**Initial Evaluation:**
- **History:** Recent chemotherapy, indwelling catheters, exposures, mucositis
- **Physical exam:** Skin (cellulitis, catheter sites), oral cavity (mucositis), lungs, abdomen, perirectal area

**Laboratory:**
- **CBC with differential** (confirm ANC <500)
- **Blood cultures x 2 sets** (peripheral + catheter if present)
- **Urinalysis + urine culture**
- **CMP** (electrolytes, renal function)
- **CRP, procalcitonin** (optional)

**Imaging:**
- **CXR** (all patients)
- **CT chest** (if persistent fever, respiratory symptoms, or concern for IFI)

**Key Point:** **Blood cultures BEFORE antibiotics** (but do NOT delay antibiotics)

---

## DURATION OF THERAPY

**Antibiotics:**
- **Continue until ANC >500 cells/μL** (if afebrile, cultures negative, clinically stable)
- **If documented infection:** Treat for full course based on infection type

**Re-Evaluation:**
- **Reassess at 3-5 days** (if persistent fever → imaging, consider antifungal)
- **Stop vancomycin after 2-3 days** if no Gram-positive infection identified

**Key Point:** **Continue antibiotics until ANC recovery (>500)**, even if afebrile

---

## SPECIAL CONSIDERATIONS

**PSEUDOMONAS AERUGINOSA:**
- High-risk pathogen in neutropenic patients
- **Double coverage if suspected** (e.g., cefepime + aminoglycoside OR cefepime + ciprofloxacin)

**STENOTROPHOMONAS MALTOPHILIA:**
- Intrinsically resistant to carbapenems
- **Treatment:** **TMP-SMX** (high-dose: 15-20 mg/kg/day TMP component)

**INVASIVE FUNGAL INFECTIONS (IFI):**
- **Candida:** Echinocandin (micafungin, caspofungin)
- **Aspergillus:** Voriconazole 1st-line
- **Mucormycosis:** Liposomal amphotericin B + surgical debridement

**Key Point:** **Prolonged neutropenia (>10 days) → Aspergillus risk** (CT chest if fever >5-7 days)

---

## PROPHYLAXIS IN HIGH-RISK PATIENTS

**Antibacterial:**
- **Fluoroquinolone** (levofloxacin 500 mg PO daily OR ciprofloxacin 500 mg PO BID)
- **Indication:** High-risk patients (AML, allogeneic HSCT)

**Antifungal:**
- **Posaconazole** 300 mg PO daily OR **Micafungin** 50 mg IV daily
- **Indication:** Prolonged neutropenia (>7 days), HSCT, AML

**Antiviral:**
- **Acyclovir** 400 mg PO BID (HSV prophylaxis if HSV-seropositive)

**PCP:**
- **TMP-SMX 1 DS 3x/week** (if T-cell defect from lymphoma, steroids, or chemotherapy)

**Key Point:** **Prophylaxis in high-risk = fluoroquinolone + antifungal (posaconazole)**

---

**Clinical Pearls:**
- **Neutropenic fever = ANC <500 + temp ≥38.3°C** (medical emergency)
- **High-risk = ANC <100, prolonged >7 days, or unstable**
- **Empiric therapy: Cefepime OR piperacillin-tazobactam** (monotherapy)
- **Add vancomycin ONLY if:** Septic shock, pneumonia, CRBSI, or severe mucositis
- **Add antifungal if persistent fever >4-7 days** (micafungin OR voriconazole)
- **Low-risk (MASCC ≥21) = outpatient oral** (cipro + Augmentin)
- **Continue antibiotics until ANC recovery (>500)**, even if afebrile
- **Prolonged neutropenia (>10 days) → Aspergillus risk** (CT chest)

**Media:** None

**Sources:** [IDSA 2010 - Neutropenic fever guidelines], [ASCO/IDSA 2024 - Outpatient management update], [NCCN 2024 - Febrile neutropenia]
